Laurie Tomlinson
Overview
Explore the profile of Laurie Tomlinson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
4980
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mahalingasivam V, Faucon A, Sjolander A, Bosi A, Gonzalez-Ortiz A, Lando S, et al.
JAMA Netw Open
. 2024 Dec;
7(12):e2450014.
PMID: 39724377
Importance: COVID-19 infection has been associated with acute kidney injury. However, its possible association with long-term kidney function is not well understood. Objective: To investigate whether kidney function decline accelerated...
2.
Baptiste P, Wong A, Schultze A, Clase C, Leyrat C, Williamson E, et al.
PLoS Med
. 2024 Sep;
21(9):e1004465.
PMID: 39283941
Background: Guidelines by the National Institute for Health and Care Excellence recommend an angiotensin receptor blocker (ARB) rather than an angiotensin-converting enzyme inhibitor (ACEi) for the treatment of hypertension for...
3.
Wiedemann M, Speed V, Cunningham C, Higgins R, Curtis H, Andrews C, et al.
Open Heart
. 2024 Aug;
11(2).
PMID: 39214534
Background: The COVID-19 pandemic disrupted cardiovascular disease management in primary care in England. Objective: To describe the impact of the pandemic on blood pressure screening and hypertension management based on...
4.
Baptiste P, Wong A, Schultze A, Clase C, Leyrat C, Williamson E, et al.
Am J Epidemiol
. 2024 Jun;
193(12):1785-1795.
PMID: 38896054
Cardiovascular disease is a leading cause of death globally. Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB), compared in the ONTARGET trial (Ongoing Telmisartan Alone and in Combination with...
5.
Currin S, George J, Holm Hansen C, Naicker S, Tomlinson L, Crampin A, et al.
Kidney Int
. 2024 Feb;
105(4):882-885.
PMID: 38307202
No abstract available.
6.
Bolt H, Suffel A, Matthewman J, Sandmann F, Tomlinson L, Eggo R
BMC Nephrol
. 2023 Aug;
24(1):234.
PMID: 37558976
Background: Acute Kidney Injury (AKI) is a multifactorial condition which presents a substantial burden to healthcare systems. There is limited evidence on whether it is seasonal. We sought to investigate...
7.
Costello R, Tazare J, Piehlmaier D, Herrett E, Parker E, Zheng B, et al.
EClinicalMedicine
. 2023 Jul;
61:102077.
PMID: 37434746
Background: The COVID-19 pandemic disrupted healthcare and may have impacted ethnic inequalities in healthcare. We aimed to describe the impact of pandemic-related disruption on ethnic differences in clinical monitoring and...
8.
Hulme W, Williamson E, Horne E, Green A, McDonald H, Walker A, et al.
Ann Intern Med
. 2023 May;
176(5):685-693.
PMID: 37126810
The COVID-19 vaccines were developed and rigorously evaluated in randomized trials during 2020. However, important questions, such as the magnitude and duration of protection, their effectiveness against new virus variants,...
9.
Eastwood S, Hughes A, Tomlinson L, Mathur R, Smeeth L, Bhaskaran K, et al.
Lancet Reg Health Eur
. 2023 Feb;
25:100557.
PMID: 36818236
Background: In the UK, previous work suggests ethnic inequalities in hypertension management. We studied ethnic differences in hypertension management and their contribution to blood pressure (BP) control. Methods: We conducted...
10.
Curtis H, Inglesby P, Mackenna B, Croker R, Hulme W, Rentsch C, et al.
Euro Surveill
. 2022 Aug;
27(33).
PMID: 35983770
BackgroundPriority patients in England were offered COVID-19 vaccination by mid-April 2021. Codes in clinical record systems can denote the vaccine being declined.AimWe describe records of COVID-19 vaccines being declined, according...